Low-calcemic oxime analogs of 1alpha,25-dihydroxy vitamin D3

摘要

The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1alpha,25-dihydroxy vitamin D₃, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compound of Formula I are useful for treating diseases which benefit from a modulation of the levels of 1alpha,25-dihydroxy vitamin D₃, for example, cell-proliferative disorders.